0013.HK HCM.US
Legend is a health company

Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results published on Wednesday. The company also reported a second consecutive year of profitability, though last year’s profit of $37.73 million was down 62.6% from 2023.

The company said that, including overseas sales in collaboration with Japan’s Takeda Pharmaceuticals, its total oncology product sales grew by 134% last year to $501 million. The company’s overall revenue decline mainly owed to a decrease in R&D income from its partners. Notably, upfront payments, regulatory milestone payments and R&D service revenue from Takeda dropped from $345.9 million in 2023 to $67 million last year.

Meanwhile, Hutchmed and Innovent Biologics (1801.HK) jointly announced that the FRUSICA-2 China Phase II/III study for the treatment of advanced renal cell carcinoma met its primary endpoint. Hutchmed’s stock opened up 3.7% on Thursday in Hong Kong, and closed up 9.41% at HK$26.15 at the midday break.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Chinese government pumping confidence into stock market

China’s state-driven stocks, and its corporate wars abroad

China's stock market rally is fast approaching its one-year mark, with the benchmark Hang Seng and Shanghai composite indexes both up around 40%. How much longer can it last, especially given the weak state of China's economy? And internet giants Meituan and DiDi have sued each other in Brazil, where they are competing in the takeout dining market. How is this case likely to end up?